



PRESS RELEASE

Biocon is the Only Asian Company to be ranked in Top 20 Global Biotech Employers for 2015

Bengaluru, India: November 03, 2015

Biocon Ltd (BSE code: 532523, NSE: BIOCON) announced today that it has earned the distinction of being the only Asian Biopharma Company to feature among the top biotechnology employers in the world as ranked by Science magazine. The ranking is a result of a global survey conducted by the American Association for the Advancement of Science (AAAS) through its affiliate Science magazine to determine which companies in the biotech and pharmaceutical industry have the best reputations as employers globally.

According to the comprehensive 2015 Web-based survey of more than 5,700 respondents on 23 different attributes, **Biocon has been recognized for three Key Attributes which are ‘Innovative leader in the industry,’ ‘Has loyal employees’ and ‘Is socially responsible’** and has been positioned at **No. 13**.

Kiran Mazumdar-Shaw, Chairperson and Managing Director, Biocon said, *“We are delighted to achieve this global recognition, which is an outcome of our efforts to create an inspiring workplace built on a strong foundation of an innovation-led ecosystem that attracts the best global talent. At Biocon, we have invested in creating a culture that pursues excellence through learning and adopting global best practices. In doing so, we have successfully earned the reputation of being the most preferred biotech employer in Asia.”*

The Top 20 companies with the best reputations as employers were shortlisted from the list of more than 181 global companies. The 2015 survey included a way for respondents to rank the biggest advantages to working in the biopharma industry. Workers voted “innovation” solidly as No. 1, followed by “working with smart colleagues” and “excellent compensation and benefits” as a close No. 2 and No. 3, respectively. Interestingly, workers ranked “having the funding and resources for research projects” as a more distant No. 4.

Top Twenty Employers for 2015

1. Novozymes (Bagsvaerd, Denmark)
2. Regeneron Pharmaceuticals, Inc. (Tarrytown, NY, United States)
3. Novo Nordisk (Bagsvaerd, Denmark)
4. Vertex Pharmaceuticals (Boston, MA, United States)
5. Alexion Pharmaceuticals (Cheshire, CT, United States)
6. Genentech (South San Francisco, CA, United States)
7. Moderna Therapeutics (Cambridge, MA, United States)
8. Roche—excluding Genentech (Basel, Switzerland)
9. Monsanto Company (Creve Coeur, MO, United States)
10. AbbVie (North Chicago, IL, United States)
11. Eli Lilly and Company (Indianapolis, IN, United States)
12. Celgene Corporation (Summit, NJ, United States)
- 13. Biocon (Bangalore, India)**



14. Abbott (Abbott Park, IL, United States)
15. Boehringer Ingelheim (Ingelheim, Germany)
16. Bayer (Leverkusen, Germany)
17. Merck KGaA (Darmstadt, Germany)
18. Biogen (Cambridge, MA, United States)
19. Gilead (Foster City, CA, United States)
20. Bristol-Myers Squibb (New York, NY, United States)

Methodology

To arrive at the final list, The US-based Brighton Consulting Group and Cell Associates first conducted a comprehensive, Web-based survey of 181 companies which had more than 5,700 respondents on 23 different attributes, including 'Corporate Image,' 'Financial Prowess,' 'Leadership and Direction,' 'Work Culture/Environment,' 'Location' and 'Academic and Intellectual Challenge.'

Survey respondents from across the globe, including North America, Europe and the Asia Pacific region, were asked to select companies which they considered the 'Best,' 'Average' and 'Worst' employers. A mathematical process was used to determine the attributes with the greatest impact on company/employer reputation. Unique ranking scores were then derived from the ratings given to each company on these attributes.

About Biocon

Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is India's largest and fully-integrated, innovation-led biopharmaceutical company. As an emerging global biopharmaceutical enterprise serving customers in over 100 countries, it is committed to reduce therapy costs of chronic diseases like autoimmune, diabetes, and cancer. Through innovative products and research services it is enabling access to affordable healthcare for patients, partners and healthcare systems across the globe. It has successfully developed and taken a range of novel biologics, Biosimilars, differentiated small molecules and affordable recombinant human insulin and analogs from 'Lab to Market'. Some of its key brands are INSUGEN®(rh-insulin), BASALOG® (Glargine), CANMAB™ (Trastuzumab), BIOMAB-EGFR™ (Nimotuzumab) and ALZUMAB™(Itolizumab), a 'first in class' anti-CD6 monoclonal antibody. It has a rich pipeline of Biosimilars and novel biologics at various stages of development including a high potential oral insulin.

For further information: **Media Contacts:**

Seema Ahuja

VP & Global Head of Communications

+91 80 6775 2222

+91 99723 17792

seema.ahuja@biocon.com**Rumman Ahmed**

Sr Manager- Corporate Communications

+91 80 6775 2223

+91 98451 04173

rumman.ahmed@biocon.com